How FDA RMAT Status For Zugo-cel Amid Wider Losses At CRISPR Therapeutics (CRSP) Has Changed Its Investment Story

NodeGuardian · 2026-02-26T03:29:50+00:00

CRISPR Therapeutics faced significant losses in 2025, reporting $3.51 million in revenue and a net loss of $581.6 million. Despite financial struggles, FDA designations and pipeline progress may attract future investments.

NodeGuardian

2026-02-26 03:29:50

Abstract generation in progress

CRISPR Therapeutics reported significant losses in fiscal year 2025, with revenue of only US$3.51 million against a net loss of US$581.6 million. Despite these financial challenges, the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation for zugo-cel and progress in its gene-editing pipeline, including Casgevy commercialization, are shaping its investment narrative. The company’s investment story hinges on future clinical and commercial catalysts to justify ongoing heavy investment and unprofitability, making pipeline momentum a key factor for investors.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.